10
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Evidence for sex difference in the CSF/plasma albumin ratio in ~20 000 patients and 335 healthy volunteers

      brief-report

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Given sex‐related differences in brain disorders, it is of interest to study if there is a sex difference in the permeability of the blood‐cerebrospinal fluid barrier ( BCSFB) and the blood‐brain barrier ( BBB). The CSF/serum albumin ratio ( Q A lb) is a standardized biomarker that evaluates the function of these barriers. In previous studies, contradictory results have been reported with respect to sex difference using this quotient, possibly because of small population sizes and heterogeneity with respect to ages. Q A lb measurements in more than 20 000 patients between 1 and 90 years visiting our hospitals revealed a significant sex difference in all age groups also when excluding patients with pathologically high CSF albumin > 400 mg/L. Similar pattern was found in 335 healthy volunteers in similar age intervals. Although also other factors are likely important, our observation is consistent with lower integrity of the brain barriers in males. If the difference in Q A lb is caused mainly by a difference in barrier function, this may require different drug doses and strategies for efficient central nervous system ( CNS) delivery in males and females, as well as it may indicate differences in brain metabolism. Moreover, our study emphasizes that different reference values should be used both for different ages and sexes.

          Related collections

          Most cited references8

          • Record: found
          • Abstract: found
          • Article: not found

          Flow rate of cerebrospinal fluid (CSF)--a concept common to normal blood-CSF barrier function and to dysfunction in neurological diseases.

          Many neurological diseases are accompanied by increased protein concentrations in the cerebrospinal fluid (CSF), described as a blood-CSF barrier dysfunction. The earlier interpretation as a "leakage" of the blood-CSF barrier for serum proteins could be revised by introduction of a "population variation coefficient" of the CSF/serum quotients for IgG, IgA and IgM (delta Q/Q) which is evaluated as a function of increasing albumin quotients (QAlb). The data presented here are based on specimens from 4380 neurological patients. These population variation coefficients were found to be constant over two orders of magnitude of normal and pathological CSF protein concentrations (QAlb = 1.6.10(-3)-150.10(-3)). This constancy indicates that there was no change in blood-CSF barrier related structures with respect to diffusion controlled protein transfer from blood into CSF and hence no change in molecular size dependent selectivity. The pathological increase of plasma protein concentrations in CSF in neurological diseases could also be explained quantitatively by a decrease of CSF flow rate due to its bifunctional influence on CSF protein concentration: reduced volume exchange, and as newly stated, increased molecular net flux into CSF without change of permeability coefficients. Again, on the basis of a changing CSF flow rate, the hyperbolic functions, which describe empirically the changing quotient ratios between proteins of different size (e.g. QIgG:QAlb) with increasing CSF protein content (QAlb) can likewise be derived from the laws of diffusion as the physiologically relevant description. The hyperbolic discrimination line between brain-derived and blood-derived protein fractions in CSF in the quotient diagrams for CSF diagnosis can be further improved on the basis of the large number of cases investigated. Other physiological and pathological aspects, such as high CSF protein values in the normal newborn, in spinal blockade, in meningeal inflammatory processes, CNS leukemia or polyradiculitis as well as animal species dependent variations can each be interpreted as due to a difference or change in the CSF flow rate.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Sex Differences in Drug Disposition

            Physiological, hormonal, and genetic differences between males and females affect the prevalence, incidence, and severity of diseases and responses to therapy. Understanding these differences is important for designing safe and effective treatments. This paper summarizes sex differences that impact drug disposition and includes a general comparison of clinical pharmacology as it applies to men and women.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Biological factors underlying sex differences in neurological disorders.

              The prevalence, age of onset, pathophysiology, and symptomatology of many neurological and neuropsychiatric conditions differ significantly between males and females. Females suffer more from mood disorders such as depression and anxiety, whereas males are more susceptible to deficits in the dopamine system including Parkinson's disease (PD), attention-deficit hyperactivity disorder (ADHD), schizophrenia, and autism spectrum disorders (ASD). Until recently, these sex differences have been explained solely by the neuroprotective actions of sex hormones in females. Emerging evidence however indicates that the sex chromosome genes (i.e. X- and Y-linked genes) also contribute to brain sex differences. In particular, the Y-chromosome gene, SRY (Sex-determining Region on the Y chromosome) is an interesting candidate as it is expressed in dopamine-abundant brain regions, where it regulates dopamine biosynthesis and dopamine-mediated functions such as voluntary movement in males. Furthermore, SRY expression is dysregulated in a toxin-induced model of PD, suggesting a role for SRY in the pathogenesis of dopamine cells. Taken together, these studies highlight the importance of understanding the interplay between sex-specific hormones and sex-specific genes in healthy and diseased brain. In particular, better understanding of regulation and function of SRY in the male brain could provide entirely novel and important insights into genetic factors involved in the susceptibility of men to neurological disorders, as well as development of novel sex-specific therapies.
                Bookmark

                Author and article information

                Contributors
                Cristina.parrado@ki.se
                Ingemar.Bjorkhem@ki.se
                Journal
                J Cell Mol Med
                J. Cell. Mol. Med
                10.1111/(ISSN)1582-4934
                JCMM
                Journal of Cellular and Molecular Medicine
                John Wiley and Sons Inc. (Hoboken )
                1582-1838
                1582-4934
                27 July 2018
                October 2018
                : 22
                : 10 ( doiID: 10.1111/jcmm.2018.22.issue-10 )
                : 5151-5154
                Affiliations
                [ 1 ] Division of Neurogeriatrics Center for Alzheimer Research Department of Neurobiology, Care Sciences, and Society Karolinska Institutet Huddinge Sweden
                [ 2 ] Clinical Neurochemistry Laboratory Institute of Neuroscience and Physiology Sahlgrenska, University Hospital Mölndal Sweden
                [ 3 ] Division of Clinical Chemistry Department of Laboratory Medicine Karolinska University Hospital Huddinge Sweden
                [ 4 ] Laboratory of Clinical Chemistry Hospital of Varese ASST‐Settelaghi Varese Italy
                Author notes
                [*] [* ] Correspondence

                Cristina Parrado‐Fernández,

                Email: Cristina.parrado@ 123456ki.se

                and

                Ingemar Björkhem

                Email: Ingemar.Bjorkhem@ 123456ki.se

                Author information
                http://orcid.org/0000-0003-2771-3206
                Article
                JCMM13767
                10.1111/jcmm.13767
                6156389
                30054982
                8b177af2-781a-47bb-951b-49c1524f76e6
                © 2018 The Authors. Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.

                This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

                History
                : 14 January 2018
                : 07 June 2018
                Page count
                Figures: 2, Tables: 0, Pages: 4, Words: 2227
                Funding
                Funded by: Swedish foundations
                Funded by: Stiftelsen för Gamla Tjänarinnor
                Funded by: Gun och Bertil Stohnes Stiftelse
                Funded by: Stockholm County Council
                Funded by: The Margaretha af Ugglas Foundation
                Funded by: Karolinska Institutet
                Categories
                Short Communication
                Short Communications
                Custom metadata
                2.0
                jcmm13767
                October 2018
                Converter:WILEY_ML3GV2_TO_NLMPMC version:version=5.4.9 mode:remove_FC converted:26.09.2018

                Molecular medicine
                brain‐barriers integrity,csf/plasma albumin ratio,sex differences
                Molecular medicine
                brain‐barriers integrity, csf/plasma albumin ratio, sex differences

                Comments

                Comment on this article